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Introduction & Aims: The distribution of the BCAT proteins has been 
extensively mapped in rodent models, and metabolic studies have established 
that BCAT transamination in the rodent brain is responsible for 30% of de novo 
glutamate synthesis.  However, to date the BCAT proteins have not been 
mapped to the human brain and their role in pathogenic conditions where 
glutamate toxicity features has not been investigated.  To this end, this study 
aimed to map the hBCAT proteins to several brain regions.  Furthermore, the 
expression of hBCAT in AD relative to matched controls was investigated and 
correlated with both physiological and pathological features of AD.  Finally, 
metabolic and inflammatory stimuli were examined for their effect on neuronal 
expression of hBCATc. 
 
Methods: Distribution of the hBCAT proteins were assessed utilising 
immunohistochemistry and imaged utilising a 12-bit camera mounted on a Leica 
DM microscope.  Western blot analysis and microscopy determined the 
expressional difference in AD compared to age and gender matched controls in 
addition to cell types responsible for the increased expression.  Further 
investigation of neuronal hBCATc expression was examined in the immortal cell 
line IMR32 utilising Western blot analysis, phase contrast microscopy, flow 
cytometry and 14C radiolabelled activity assay. 
 
Results & Discussion: For the first time this work demonstrates key 
differences between the animal model of BCAA metabolism and humans.  All 
brain regions contained cell types labelled for hBCATc and hBCATm.  However, 
while this work mirrored animal models in that hBCATc was localised 
specifically to neurons, hBCATm was absent from astrocytes and instead 
labelled the vasculature – contrary to animal models.  Another novel finding of 
this work links altered aminotransferase expression to AD pathology.  An 
increase of hBCATm expression of +117% (p = 2.29 x 10-4) and +143% (p = 
7.70 x 10-5) in the frontal and temporal cortex of AD subjects relative to matched 
controls demonstrates the disease association of hBCATm.  A non-significant 
increase of 32% was observed for hBCATc in the frontal region.  With hBCATm 
expression correlating with Braak stage in both the frontal (p = 1.2 x 10-5, ρ 
+0.468) and temporal (p = 3.4 x 10-4, ρ+0.391) cortex this work posits that 
altered BCAA metabolism is occurring simultaneously with AD progression and 
may be a novel therapeutic target for the treatment of dementia.  Another novel 
aspect of this work also demonstrates cell surface expression of hBCATc and 
relates this to mTOR signalling.  Altered cell surface and protein expression was 
investigated with functional activity.  Together this data demonstrated 
expressional, functional or activity changes in hBCATc due to glutamate, 
insulin, leucine, TNFα and IL1α. 
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Grx – Glutaredoxin  
GSNO – S-nitrosoglutathione  
GSH – Glutathione reduced  
GSSG – Glutathione oxidized  
hBCATc – Human branched chain aminotransferase (cytosolic isoform)  
hBCATm – Human branched chain aminotransferase (mitochondrial isoform)  
HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HRP – Horseradish peroxidase  
IMR32 – Human neuroblastoma cell line  
IL – Interleukin 
IPTG – Isopropyl β-D-1-thiogalactopyranoside  
KIC – Ketoisocaproate  
KIV – Keto-isovaleric acid  
KMV - Keto-β-methylvalerate 
L1 – Large neutral amino acid transporter 1 
LDS – Lithium dodecyl sulphate  
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nAChR – Nicotinic acetylcholine receptor 
NADH – Nicotinamide adenine dinucleotide 
NEAA – Non essential amino acids 
NMDA – N-methyl-D-aspartic acid  
NOS – Nitric oxide synthetase 
MMSE – Mini-mental state examination 
MSUD – Maple syrup urine disease 
mTOR – Mammalian target of Rapamycin  
mTORC1 – Mammalian target of Rapamycin complex 1 
mTORC2 – Mammalian target of Rapamycin complex 2 
NADPH – Nicotinamide adenine dinucleotide phosphate  
NO – Nitric oxide  
PDI – Protein Disulphide isomerase  
PKC – Protein kinase C  
PLP – Pyridoxal phosphate  
PMP – Pyridoxine monophosphate  
PMSF – Phenylmethyl sulfonyl fluoride 
RIPA – Radioimmunoprecipitation assay buffer  
RPMI - Roswell park memorial institute medium 
SDS – Sodium dodecyl sulphate  
TBST – Tris-Buffered Saline/Tween  
TCA – Trichloroacetic acid  
TEMED – Tetramethylethylenediamine  
Trx – Thioredoxin  
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TNF – Tissue necrosis factor 
UO – ubiquionone oxidoreductase 
ZIP – zipper interacting protein 
